Figure 1.
Management approach for patients who achieve remission after CD19 CAR T-cell therapy. The scheme highlights key factors to consider. blina, blinatumomab; CARTS, CAR T cells; MRD, minimal residual disease.
Management approach for patients who achieve remission after CD19 CAR T-cell therapy. The scheme highlights key factors to consider. blina, blinatumomab; CARTS, CAR T cells; MRD, minimal residual disease.